MetabolicTIRZEPATIDE
10MG
$75
Description
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual incretin mechanism provides superior metabolic control compared to GLP-1-only agonists. The GLP-1 component suppresses appetite, slows gastric emptying, and stimulates insulin secretion, while the GIP component enhances beta cell function, improves fat metabolism, and may contribute to central appetite regulation. Tirzepatide is FDA-approved as both Mounjaro (for type 2 diabetes) and Zepbound (for weight management).
Potential Benefits
Research Notes
The SURPASS and SURMOUNT clinical trial programs, published in the New England Journal of Medicine and The Lancet, demonstrated tirzepatide's superiority over semaglutide in head-to-head comparisons. SURMOUNT-1 showed 22.5% average body weight reduction at the highest dose over 72 weeks. Tirzepatide received FDA Breakthrough Therapy designation and represents a paradigm shift in metabolic research with its dual incretin approach.
Usage Information
For research and educational purposes only. Consult with a qualified professional before use.
All peptides must be refrigerated upon receipt.
RESEARCH PURPOSES ONLY
This product is intended for research and educational purposes only. Not intended for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.